Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04597437 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Study acronym: ZAP-DENGUE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 30, 2026 → Aug 31, 2027
See other at-risk trials from George Washington University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 30, 2026 to Aug 31, 2027v16
  2. Primary and study completion dates: Sep 30, 2025 to Sep 30, 2026v15
  3. Study sites: 1 to 2v14
  4. Eligibility criteria shortened, about 14 words
    • Site details revised
    • Collaborators: 3 to 4
    v13
  5. Phase: Early Phase 1 to Phase 2v12
Show 10 earlier versionsHide 10 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jun 30, 2024 to Sep 30, 2025
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2024 to Mar 15, 2024
    v11
  2. Start date: Dec 1, 2023 to Mar 1, 2024v10
  3. Primary and study completion dates: Aug 30, 2023 to Jun 30, 2024
    • Start date: Aug 1, 2023 to Dec 1, 2023
    v9
  4. Start date: Jun 1, 2023 to Aug 1, 2023v8
  5. Start date: Mar 1, 2023 to Jun 1, 2023v7
  6. Start date: Jan 1, 2023 to Mar 1, 2023v6
  7. Start date: Nov 1, 2022 to Jan 1, 2023v5
  8. Start date: Sep 1, 2022 to Nov 1, 2022
    • Collaborators: 4 to 3
    v4
  9. Eligibility criteria expanded, about 25 words
    • Study description expanded, about 15 words
    • Collaborators: 5 to 4
    v3
  10. Primary and study completion dates: Sep 30, 2022 to Aug 30, 2023
    • Start date: Oct 1, 2021 to Sep 1, 2022
    • Collaborators: 4 to 5
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
Trial Details
NCT Number NCT04597437
Lead Sponsor George Washington University
Collaborators: Naval Medical Research Center, Clinica de la Costa, Global Disease Research, Universidad Libre de Barranquilla
Conditions
(from sponsor)		 Dengue Fever
Related terms Dengue
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov